From our Thought Leaders in Health Law video series: The Inflation Reduction Act (IRA) introduces significant changes in prescription drug pricing, including the establishment of the Medicare Drug Price Negotiation Program and the Medicare Prescription Drug Inflation Rebate Program to control drug prices.
The IRA includes a redesign of the Medicare Part D benefit, which began with the announcement of 10 Medicare Part D drugs open for negotiation. This video highlights the challenges and complexities during the multi-year IRA implementation and emphasizes the penalties for noncompliance with IRA provisions.
What does this mean for you?
- Drug companies will need to ensure compliance with the new regulations and reporting requirements introduced by the IRA. Noncompliance can result in penalties, which can be financially significant.
- Implementing the IRA provisions may pose operational, legal, and logistical challenges for drug companies. Companies should invest in compliance efforts, data tracking, and reporting systems.
For more information on the IRA, visit: https://www.ebglaw.com/trending-issues/inflation-reduction-act
The Thought Leaders in Health Law® video series tracks the latest trends in multiple areas of the health care and life sciences industries, featuring attorneys and advisors from Epstein Becker Green and EBG Advisors.
